Lupus

A French nationwide study has described COVID-19 outcomes in patients with systemic lupus erythematosus.

Alfred Kim talks about the initial promise of hydroxychloroquine for COVID-19 and why it did not stand up to later scrutiny (13:06).

Among patients with systemic lupus erythematosus receiving treatment with hydroxychloroquine, low drug levels in the blood are associated with an elevated risk for arterial and venous thrombosis events, researchers report.

Click through for more information on this expanded indication

Patients with new-onset lupus nephritis may be more likely to achieve a complete renal response if initially given a higher dose of prednisone than currently recommended, findings indicate.